scPhar­ma­cu­ti­cals rais­es $45M B round; Strug­gling Ni­valis and Acu­ra take stock of “strate­gic al­ter­na­tives”

• Lex­ing­ton, MA-based scPhar­ma­ceu­ti­cals, which is tak­ing gener­ic drugs and re­for­mu­lat­ing them for sub­cu­ta­neous in­jec­tion, has raised $45.6 mil­lion in its Se­ries B round. The round was co-led by Or­biMed and a whol­ly-owned sub­sidiary of Sun Phar­ma­ceu­ti­cal In­dus­tries, Sun Phar­ma. Ex­ist­ing in­vestors 5AM Ven­tures and Lund­beck­fond Ven­tures par­tic­i­pat­ed in the fi­nanc­ing.

• A month af­ter Ni­valis $NVLS saw its shares crater af­ter its lead pro­gram flunked a mid-stage tri­al, the biotech is look­ing at its strate­gic al­ter­na­tives while cut­ting back on costs. Ni­valis says it will com­plete its on­go­ing SNO-7 tri­al of cavoson­stat in pa­tients with CF who are cur­rent­ly tak­ing Ka­ly­de­co (iva­caftor), which is ex­pect­ed to be com­plet­ed in the first quar­ter of 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER